Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals    VRTX

VERTEX PHARMACEUTICALS

(VRTX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/20/2020 10/21/2020 10/22/2020 10/23/2020 10/26/2020 Date
214.54(c) 211.38(c) 210.08(c) 211.58(c) 206.0375 Last
2 924 795 2 775 667 2 380 567 1 715 758 1 732 383 Volume
-2.71% -1.47% -0.62% +0.71% -2.62% Change
More quotes
Financials (USD)
Sales 2020 6 010 M - -
Net income 2020 2 422 M - -
Net cash position 2020 6 176 M - -
P/E ratio 2020 23,0x
Yield 2020 -
Sales 2021 6 797 M - -
Net income 2021 2 639 M - -
Net cash position 2021 9 566 M - -
P/E ratio 2021 21,1x
Yield 2021 -
Capitalization 55 110 M 55 110 M -
EV / Sales 2020 8,14x
EV / Sales 2021 6,70x
Nbr of Employees 3 000
Free-Float 72,2%
More Financials
Company
Vertex Pharmaceuticals specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales break down by type of income as follows: - income from sales of products (99.9%); - royalties and income from partnership, research, and development agreements (0.1%). Net sales break down geographically as follows:... 
More about the company
Notations Surperformance© of Vertex Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
All news about VERTEX PHARMACEUTICALS
10:15aVERTEX PHARMACEUTICALS : quaterly earnings release
10/20VERTEX PHARMACEUTICALS : to Announce Third-Quarter 2020 Financial Results on Oct..
AQ
10/19VERTEX PHARMACEUTICALS : to Announce Third-Quarter 2020 Financial Results on Oct..
BU
10/16VERTEX PHARMACEUTICALS : quaterly earnings release
10/15Health Care Down On Rotation To Value Sectors -- Health Care Roundup
DJ
10/15Vertex Shares Plunge After Biotech Drops Closely Watched Drug Prospect
DJ
10/15VERTEX PHARMACEUTICALS : Down After Study Discontinued
DJ
10/15Vertex Pharmaceuticals Down Over 18%, on Pace for Largest Percent Decrease Si..
DJ
10/15Wall Street falls on stalling economic rebound, stimulus impasse
RE
10/15Stock Futures Drop on Rising Covid-19, Economic Risks
DJ
10/15Stock Futures Drop on Rising Covid-19, Economic Risks
DJ
10/15Futures fall on stalling economic rebound, stimulus impasse
RE
10/15Stock Futures Drop on Rising Covid-19, Economic Risks
DJ
10/15VERTEX PHARMACEUTICALS : Provides Update on its Clinical Programs Targeting Alph..
AQ
10/15Stock Futures Drop on Rising Covid-19, Economic Risks
DJ
More news
News in other languages on VERTEX PHARMACEUTICALS
10/16VERTEX PHARMACEUTICALS : Veröffentlichung des Quartalsergebnisses
10/16VERTEX PHARMACEUTICALS : publication des résultats trimestriels
09/24VERTEX PHARMACEUTICALS : präsentiert auf virtuellen Mukoviszidose-Konferenzen in..
09/24VERTEX PHARMACEUTICALS : présentera de nouvelles données lors de conférences eur..
07/27VERTEX PHARMACEUTICALS : Veröffentlichung des Halbjahresergebnisses
More news
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 298,70 $
Last Close Price 211,58 $
Spread / Highest target 60,7%
Spread / Average Target 41,2%
Spread / Lowest Target 15,8%
EPS Revisions
Managers
NameTitle
Reshma Kewalramani President, Chief Executive Officer & Director
Jeffrey M. Leiden Executive Chairman
Charles F. Wagner Chief Financial Officer & Executive Vice President
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Carmen Bozic Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS-3.37%55 110
GILEAD SCIENCES, INC.-6.45%76 214
REGENERON PHARMACEUTICALS54.42%61 014
WUXI APPTEC CO., LTD.58.33%37 775
BEIGENE, LTD.80.38%27 097
GENMAB A/S49.17%22 988